Mandate
To provide recommendations to the Board and the Registrar on matters relating to pharmacy legislation and policy review.
Membership
Mona Kwong (Chair, effective December 2018)
Jeremy Walden (Chair, until December 2018)
Christine Paramonczyk (staff resource)
Bal Dhillion (effective January 2019)
Christopher Szeman (until October 2018)
Justin Thind
Sorell Wellon (until October 2018)
Number of Meetings: 4
Accomplishments of the Year
Over the past year, the Legislation Review Committee recommended the following changes to policy, bylaws, fees, and Standards of Practice:
| Legislation |
Amendments |
|---|
| Health Professions Act Bylaws |
April 2019
- Approval to file HPA Fee and Form amendments with the Minister of Health.
September 2018
- Approval to publicly post a Patient Relations Standard for a 90-day period.
|
|
Pharmacy Operations and Drug Scheduling Act Bylaws
|
April 2019
- Approval to publicly post PODSA Fee and Form amendments for a 90-day period.
September 2019
- Approval to file PODSA fee amendments with the Minister of Health.
- Approval to file bylaw amendments regarding electronic recordkeeping with the Minister of Health.
November 2018
- Approval to publicly post the removal of Schedules “C” and “E” regarding telepharmacy license requirements and related bylaw amendments.
|
| Professional Practice Policies (PPP) et al |
April 2018
- Approval of housekeeping amendments to PPP-66 “Opioid Agonist Treatment”
- Approval of amendments to PPP-3 “Pharmacy References” and PPP- 74 “Community Pharmacy Security”
- Approval to repeal PPP-26 “Pharmacy Distribution of Alternative and
- Complementary Health Products” and PPP-32 “Dispensing Multi-Dose Vials”
June 2018
- Approval of a PPP-67 “Injectable Opioid Agonist Treatment” to be effective on September 1, 2018.
- Approval of a PPP-67 Policy Guide – “Injectable Hydromorphone Maintenance Treatment (2018).”
- Approval of a PPP-69 “Pharmacy Manager Education” to be effective September 1, 2018.
September 2018
- Approval of housekeeping amendments to PPP-58 “Medication Management (Adapting a Prescription)”, PPP-66 “Opioid Agonist * Treatment” and PPP-67 “Injectable Opioid Agonist Treatment.”
|
| Drug Schedules Regulation ("DSR") |
June 2018
- Approval of multiple DSR amendments to improve alignment with the National Drug Schedules, the Prescription Drug List made under the Food and Drugs Act (Canada), and the Schedules to the Controlled Drugs and Substances Act.
November 2018
- Approval to pursue scheduling by reference to federal legislation and the National Drug Schedules established by the National Association of Pharmacy Regulatory Authorities.
- Approval of housekeeping amendments with respect to Codeine, Lisdexamfetamine dimesylate, and Nicotine for filing with the Minister of Health.
- Approval of amendments with respect to Cannabinoids for filing with the Minister of Health.
|
